Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?
CRISPR Trial Halt Triggers Sell-Off Intellia’s stock was hammered on Monday after the biotech stunned investors with news of a clinical trial pause. Before the opening bell, the Cambridge, MA-based company announced